Clinical Trial

A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated February 26, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a multi center, open-label, dose escalation, Phase I/IIa study of EF-009 in up to 30 patients with borderline resectable and unresectable pancreatic cancer.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-05-07; most recent amendment 2025-02-24.
Trial Details
NCT Number NCT04381130
Lead Sponsor Everfront Biotech Co., Ltd.
Conditions Pancreatic Cancer
Enrollment 30 participants
Start Date 2025-09-01
Primary Completion 2025-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-26